Nature Reviews Drug Discovery

Article	Citations
A specific biomarker for insoluble tau	1657
Targeting tumour-associated bacteria	1018
A new path to targeted protein degradation?	789
Neutralizing Zika virus	746
The improving benefit–risk balance of phase I cancer trials	654
Tumour cells get a dendritic cell makeover	652
Glucose-sensitive insulin protects against hypoglycaemia	603
Hypoimmune iPSCs escape immune detection	585
Lipid nanoparticle ferries therapeutic mRNA to the placenta	496
New antibiotic for urinary tract infections nabs FDA approval	484
FDA new drug approvals in Q1 2023	460
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	460
Apolipoprotein L2 inhibitor mitigates fibrosis	456
FDA approves second TTR stabilizer for cardiac amyloidosis	449
Targeting drug-resistant glioblastoma	442
Degrading cell-free DNA to prevent recurrent stroke	415
FDA approves a c-MET-targeted ADC for lung cancer	413
Anti-tau antibody stumbles in phase II Alzheimer trial	402
AI serves up target and inhibitor for lung fibrosis	348
Analysis of a decade of post-authorisation studies for medicines approved by the EMA	336
mRNA vaccines for infectious diseases — advances, challenges and opportunities	317
Target identification and assessment in the era of AI	304
Targeting the Hippo pathway in cancer	275
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	268
2022 FDA approvals	262

Chemical engineering of CRISPR–Cas systems for therapeutic application	241
Small-molecule discovery through DNA-encoded libraries	234
Increasing the potency of T cell therapies	232
Small molecule improves muscle function in myasthenia gravis	227
Pushing both sides of the drug pricing aisle	223
TCR-engineered T cells get personal	221
R&D re-balancing act	215
2025’s FDA approvals by regulatory designations	214
Rewired proteostasis in KRAS inhibitor resistance	207
An allosteric site on cereblon	204
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	198
Mimicking the health benefits of exercise	195
Host-directed antiviral blocks SARS-CoV-2 entry	194
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	192
Combating antimicrobial resistance in malaria, HIV and tuberculosis	181
FDA new drug approvals in Q2 2023	169
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	166
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	165
Roads and detours for CAR T cell therapy in autoimmune diseases	160
A peptide-guided strategy for kinase activation	160
The significance of blockbusters in the pharmaceutical industry	157
The antibody–drug conjugate landscape	155
A renaissance in targeting the PI3K/AKT/mTOR pathway	150
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	147
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	147
Novel drug targets in 2025	143
Inhibiting ASGR1 boosts cholesterol removal	141
Antibody–drug conjugates come of age in oncology	139
Pulsatile FXR agonism	135
Amylin takes another shot at the obesity prize	132
Multi-TACs target solid tumours	128
Immunology on the brain	123
Reducing IL-2 toxicity	123
Agonist antibody lowers blood pressure	117
Antiviral peptide nabs FDA approval for hepatitis delta virus infection	113
Monkeypox mRNA vaccine protects mice and macaques	113
The unglamourous AI wins that are quietly transforming drug discovery and development	110
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	106
Neglected tropical diseases go global	105
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	101
Targeting the ECM in melanoma	98
Redirecting mast cells for antigen-specific cancer immunotherapy	97
Ribosome inhibitor combats bacterial drug resistance	95
Designing G-protein-selective allosteric modulators	95
The European Innovation Network as a hub for medicines innovation in Europe	93
Anti-IL-11 antibody shows anti-ageing properties	92
Targeting claudins in cancer	89
Realizing the potential of agonistic antibody immunotherapy	87
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	86
LRRK2-targeted Parkinson disease drug advances into phase III	86

Frameworks for transformational breakthroughs in RNA-based medicines	85
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	84
Engineered parasite delivers proteins to the brain	83
Engineering a compact genome-editing tool	83
Delivering genome editing tools to primary cells	79
Upcoming market catalysts in Q4 2023	77
The non-small-cell lung cancer drug market	76
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	75
Broader horizons for cereblon glue degraders	70
Publisher Correction: Roflumilast	68
Accelerating precision oncology by converging pragmatic trials and real-world evidence	68
Covalent inhibitor engages oncogenic AKT kinase	66
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor	66
A rush of CRISPR to the lungs	66
RNA structure guides antiviral ASO design	66
Investigating the origins of recent pharmaceutical innovation	64
Understanding Ras inhibitor resistance	62
AAV-based in vivo gene therapy for neurological disorders	61
Trends in the development of cellular and gene therapy in China	57
Betting on β-catenin inhibitors in oncology	54
Targeting protein disorder: the next hurdle in drug discovery	53
CAR T cell therapy for solid cancer scores first approval in China	53
Three-step cures for autoimmune diseases?	52
MYC in cancer: from undruggable target to clinical trials	52
V-ATPase inhibitor targets Ras-mutant cancers	51
Designing novel macrocyclic drugs	49
Upcoming market catalysts in Q4 2024	49
Can large, simple trials bring drug developers back to common diseases?	48
Towards a broad-spectrum antiviral agent	47
Calico, Alphabet’s anti-ageing play, goes it alone	45
De novo design of macrocycles	44
Halda secures biggest induced-proximity deal yet, with J&J’s US$3 billion buy out	44
Microbial ‘dark matter’ yields new antibiotic	43
Understanding LAG3 immune checkpoint function	43
Neurotensin receptor modulator safely tackles pain	43
FDA approves cell-sheet-based gene therapy for severe skin disease	43
Cartilage regeneration for osteoarthritis	43
Analysis of China-to-West pharmaceutical licensing deals in 2024	41
Hinge modifier approach opens door to drugging HECT E3 ligases	40
PPAR agonists provide new treatment options for inflammatory liver disease	39
A new drug target for NRAS(Q61) mutant-expressing cancers	39
2023 FDA approvals: unprecedented volume at moderate value	39
Glue-based KRAS inhibitors make their debut cancer trial mark	36
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	36
Novel strategies to manage CAR-T cell toxicity	35
RNA delivery heats up cold tumours	35
Can multispecific biologics break the efficacy ceiling?	35
The evolution of the obesity drug market	34
RNA chemistry and therapeutics	34
The case for cell-penetrating peptides	33
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	32
p38α inhibition restores axonal transport	32
Transcription reprogramming to enhance CAR-T cell function	31
Synthetic cytokine circuit targets solid tumours	31
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	31
Designing closure-stabilizing integrin inhibitors	30
FDA approves 21-valent pneumococcal vaccine	30
A step closer to in vivo editing of haematopoietic stem cells	30
Designing insulin receptor agonists	29
PD1 × VEGF blocking bispecifics for cancer draw big backing	29
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	28
Novel schizophrenia therapy filed for FDA approval	28
FDA approves PI3Kα inhibitor that does double duty as a degrader	28
CAR T cells take to the airways	26
Rebalancing cardiolipin biosynthesis to treat cardiomyopathy	26
FDA approves first factor XIIa inhibitor, for hereditary angioedema	26
A faster route to antidepressant activity	25
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	25
Enhancing CAR-T cell efficacy through IFN ablation	25
Genome-editing medicinal products: the EMA perspective	25
Unmet needs in vaccine development	24
Top product forecasts for 2025	24
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety	23
RNAi-based drug design: considerations and future directions	23
FDA approves novel cell therapy made with haematopoietic stem cells, Tregs and T cells	22
Sequential immunotherapy: towards cures for autoimmunity	22
HuR degrader knocks down BRAF in cancer	22
Targeting galectin-driven regulatory circuits in cancer and fibrosis	22
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	22
Safety considerations for cereblon-recruiting targeted protein degraders	21

Acyl-lysine reader inhibitor blocks AML progression	21
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	21
Synthesizing portimines	21
In vivo CAR T cells move into clinical trials	21
Understanding the effects of antibiotic combinations	21
Epigenetic editor silences prion protein	20
Bacteria tag tumours for CAR-T cell attack	20
Treating cannabis use disorder	20
Stalled molecular motor inhibits tumour growth	20
ASO targets DNA repair protein to combat Huntington disease	19
Brain glucose mediates amphotericin B tolerance	19
Building on the momentum of N-of-1 base editor therapies for rare diseases	19
CRISPR activation tackles neurodevelopmental disorders	18
Lilly buys Verve and its in vivo gene editors for up to US$1.3 billion	18
Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning	18
Kinase inhibitors trigger target degradation	17
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	17
Neurons give metastatic cells a push	17
Trends in the drug target landscape for autoimmune diseases	17
In vivo CAR T cells gain traction, with AbbVie’s US$2.1 billion acquisition of Capstan Therapeutics	17
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	17
Dose-finding and optimization in drug development for rare diseases	17
The KRAS crowd targets its next cancer mutations	16
Dual-vector gene therapy for hearing loss secures first FDA approval	16
Open-science drug discovery for COVID-19	16
Trends in the landscape of clinical trials of innovative drugs in China since 2015	16
Insights into new approach methodology innovation: an EMA perspective	16
A guide to effective drug development through nonprofit models	16
FDA approves GLP-1 pill for obesity	15
Advancing ferroptosis-targeted therapies	15
Advanced technologies for the development of infectious disease vaccines	15
The changing face of UK academic drug screening in the past decade	15
Towards mRNA therapeutics 2.0	15
Trustworthy AI for safe medicines	15
A new antibiotic for A. baumannii	14
FDA releases tissue-agnostic cancer drug draft guidance	14
Understanding sphingosine-1-phosphate transport	14
Alnylam scores big pharma support for angiotensinogen silencer	14
Gene editing addresses antithrombin deficiency	14
Understanding immunomodulatory antibody agonism	14
Phosphatase inhibitor drives anticancer immune responses	13
Ramping up mitochondrial DNA replication	13
Setting GPCRs free	13
Upcoming market catalysts in Q3 2023	13
FDA approves first claudin-18.2-targeted antibody for gastric cancer	13
Soluble Notch agonists drive T cell production	13
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease	12
The ovarian cancer drug market	12
The renal cell carcinoma drug market	12
Membrane transporters in drug development and as determinants of precision medicine	12
FDA approves first two drugs for rare Niemann–Pick disease	12
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	12
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities	12
Macrophages as tools and targets in cancer therapy	11
Targeting cytokine networks in neuroinflammatory diseases	11
Repurposing beta-blockers in breast cancer	11
FDA approves first chikungunya vaccine	11
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	11
Antibody drug conjugate combats inflammation	11
BacPROTAC to treat tuberculosis	11
Designing GPCR-targeted miniproteins	11
Targeting expanded trinucleotide repeats	11
Chromatin-targeted drug discovery at “a very special moment”	11
Mapping cysteine ligandability	11
Boosting CAR T cell efficacy	10
The potential of innovative trial design for efficiently evaluating repurposed drugs	10
Targeting ephrin signalling in sepsis	10
AhR inhibition promotes axon regeneration	10
In vivo CAR T purchase spree continues with Lilly deal worth up to US$7 billion	10
Understanding semaglutide action in the brain	10
RNF41 reverses liver fibrosis	10
Developing an IKZF2 glue degrader	10
How multispecific molecules are transforming pharmacotherapy	10
Roche buys MASH contender for up to US$3.5 billion	10
Trikines rewire STAT signalling	10
2022 FDA approval number dips: a COVID-19 hangover?	9
New therapeutic candidate for Chagas disease	9
FDA approves PI3K inhibitor for a rare immune disorder	9
FDA approves BTK inhibitor for chronic hives	9
New route to target RAS	9
Opportunities for mitochondrial disease gene therapy	9
FDA approves second anti-amyloid antibody for Alzheimer disease	8
Fibrosis: cross-organ biology and pathways to development of innovative drugs	8
Advances in the treatment of systemic lupus erythematosus	8
Targeting immunogenic cell stress and death for cancer therapy	8
2023 FDA approvals	8
Lipid flippase inhibitor tackles drug-resistant fungi	8
Deuterium in drug discovery: progress, opportunities and challenges	8
Novel drug targets in 2023	8
Top product forecasts for 2026	8
Oral macrocyclic PCSK9 inhibitor secures FDA approval	8
BCMA-targeted bispecific gets first green light, in the EU	8